Disinhibition of the superior colliculus restores orienting to visual stimuli in the hemianopic field of the cat.
Following unilateral removal of all known visual cortical areas, a cat is rendered hemianopic in the contralateral visual field. Visual orientation can be restored to the blind hemifield by transection of the commissure of the superior colliculus or by destruction of the superior colliculus (SC) or the substantia nigra pars reticulata (SNpr) contralateral to the cortical lesion. It is hypothesized that a mechanism mediating recovery is disinhibition of the SC ipsilateral to the cortical lesion. The ipsilateral nigrotectal projection exerts a robust inhibitory tone onto cells in the SC. However, ibotenic acid destruction of SNpr neurons, which should decrease inhibition onto the SC, does not result in recovery. The failure of ipsilateral SNpr lesions to produce recovery puts into question the validity of SC disinhibition as a mechanism of recovery. We directly tested the disinhibition hypothesis by reversibly disinhibiting the SC ipsilateral to a visual cortical lesion with a gamma-aminobutyric acid (GABA)A antagonist, bicuculline methiodide. In accordance with the hypothesis, transient disinhibition of the SC restored visual orienting for several hours in three of eight animals. Recovery was not a volume or pH effect and was distinct from the release of irrepressible motor effects (i.e., approach and avoidance behaviors) seen within the first hour after injection. Thus, in the absence of all visual cortical areas unilaterally, disinhibition of the SC can transiently restore the ability of the cat to orient to visual stimuli in the previously "blind" hemifield.
Ciaramitaro
V M
VM
Department of Neuroscience, University of Pennsylvania, Philadelphia 19104, USA.
Todd
W E
WE
Rosenquist
A C
AC
D000818:Animals; D001522:Behavior, Animal / Q000502:physiology; D001640:Bicuculline / Q000031:analogs & derivatives / Q000494:pharmacology; D002415:Cats / Q000502:physiology*; D007839:Functional Laterality / Q000502:physiology; D018756:GABA Antagonists / Q000494:pharmacology; D007267:Injections; D008297:Male; D009433:Neural Inhibition / Q000187:drug effects / Q000502:physiology*; D009949:Orientation / Q000502:physiology*; D010775:Photic Stimulation; D012074:Remission Induction; D013477:Superior Colliculi / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology*; D014786:Vision Disorders / Q000473:pathology / Q000503:physiopathology*; D014793:Visual Cortex / Q000473:pathology; D014794:Visual Fields / Q000502:physiology*
D018756:GABA Antagonists; C017069:bicuculline methiodide; D001640:Bicuculline